Shanton Pharma
Private Company
Funding information not available
Overview
Shanton Pharma is a private, clinical-stage biotech headquartered in Princeton, NJ, with a targeted focus on inflammatory and metabolic disorders, particularly gout. The company's lead asset, SAP-001, has achieved Fast Track designation and completed a successful End-of-Phase 2 meeting with the FDA, positioning it for a pivotal Phase 3 trial in refractory gout. Led by an experienced management team with deep industry expertise, Shanton is advancing a pipeline of small molecule therapies aimed at significant markets with high unmet need.
Technology Platform
Focused on advanced small molecule drug research and development for specific inflammatory and metabolic pathways, with no broad platform explicitly described.
Opportunities
Risk Factors
Competitive Landscape
The gout market is competitive with established xanthine oxidase inhibitors (allopurinol, febuxostat) and newer agents like lesinurad and pegloticase for refractory cases. Shanton's SAP-001 aims to be a best-in-class oral therapy for patients failing standard care, competing against injectable biologics and other late-stage pipeline candidates from other biotechs.